Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 10/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15798472 | 0.83 | NR4A2 (0.41) | NR4A2CREBBPGABRA1GABRG2GABRB3 | |
| SCHEMBL6937497 | 0.81 | ALDH1A1 (0.51) | GABRA1GABRA3KDM4EALDH1A1LMNA | |
| SCHEMBL24169816 | 0.79 | PBRM1 (0.39) | BRD4KDM4EALDH1A1LMNAGAA | |
| SCHEMBL7586830 | 0.79 | ALDH1A1 (0.42) | KDM4EALDH1A1GAAHPGD | |
| SCHEMBL22679184 | 0.79 | BRD4 (0.41) | CREBBPBRD4KDM4EALDH1A1GAA | |
| SCHEMBL28945708 | 0.78 | BRD4 (0.42) | NR4A2CREBBPBRD4MAP2K1KDM4E | |
| SCHEMBL19586524 | 0.78 | KDM4E (0.41) | NR4A2CREBBPBRD4KDM4EALDH1A1 | |
| SCHEMBL5231392 | 0.73 | MYC (0.49) | NR4A2GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL28104144 | 0.71 | SLC22A6 (0.44) | KDM4EALDH1A1GAASMN1; SMN2HPGD | |
| SCHEMBL69740 | 0.71 | NR4A2 (0.48) | NR4A2CREBBPMAP2K1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116064598-B | Nucleic acid vaccine for coronavirus | 苏州艾博生物科技有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-116615472-A | Polymer conjugated lipid compounds and lipid nanoparticle compositions | 苏州艾博生物科技有限公司 | 2023-08-18 | — | — | CN | disclosed |
| CN-116332830-A | Lipid compounds and lipid nanoparticle compositions | 苏州艾博生物科技有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-116064598-A | Nucleic acid vaccine for coronavirus | 苏州艾博生物科技有限公司 | 2023-05-05 | — | — | CN | disclosed |
| US-11266643-B2 | Triaryl compounds for treatment of PD-L1 diseases | CHEMOCENTRYX, INC. (US) | 2022-03-08 | — | — | US | disclosed |
| US-20220009985-A1 | Methods and Compositions Relating to p62/SQSTM1 for the Treatment and Prevention of Inflammation-Associated Diseases | CURELAB ONCOLOGY INC (US) | 2022-01-13 | — | — | US | disclosed |
| WO-2021071979-A1 | COMPOSITIONS AND METHODS FOR INCREASING EPITHELIAL BARRIER FUNCTION | BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-04-15 | — | — | WO | disclosed |
| US-20200383979-A1 | TRIARYL COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES | CHEMOCENTRYX, INC. | 2020-12-10 | — | — | US | disclosed |
| US-20200338176-A1 | METHODS AND COMPOSITIONS RELATING TO P62 FOR THE TREATMENT AND PROPHYLAXIS OF CANCER | CURELAB ONCOLOGY INC (US) | 2020-10-29 | — | — | US | disclosed |
| EP-3089753-B1 | METHODS AND COMPOSITIONS RELATING TO P62/SQSTM1 FOR THE TREATMENT AND PREVENTION OF INFLAMMATION-ASSOCIATED DISEASES | CURELAB ONCOLOGY INC (US) | 2020-08-26 | — | — | EP | disclosed |
| WO-2003049525-A2 | METHODS AND MATERIALS FOR THE PRODUCTION OF ORGANIC PRODUCTS IN CELLS OF $I(CANDIDA) SPECIES | CARGILL DOW LLC (US) | 2003-06-19 | — | — | WO | disclosed |
| WO-2001068859-A9 | IL-17 RECEPTOR LIKE MOLECULES AND USES THEREOF | AMGEN INC (US) | 2002-12-19 | — | — | WO | disclosed |
| EP-1265924-A2 | IL-17 RECEPTOR LIKE MOLECULES AND USES THEREOF | Amgen Inc. (US) | 2002-12-18 | — | — | EP | disclosed |
| EP-1266002-A2 | IL-17 RECEPTOR LIKE MOLECULES AND USES THEREOF | Amgen Inc., (US) | 2002-12-18 | — | — | EP | disclosed |
| WO-2002094859-A2 | MAGE-A1 PEPTIDES FOR TREATING OR PREVENTING CANCER | AVENTIS PASTEUR LIMITED (CA) | 2002-11-28 | — | — | WO | disclosed |
| EP-1238077-A1 | TNFR/OPG-LIKE MOLECULES AND USES THEREOF | Amgen Inc., (US) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001068859-A2 | IL-17 RECEPTOR LIKE MOLECULES AND USES THEREOF | AMGEN INC. (US) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001068705-A2 | IL-17 RECEPTOR LIKE MOLECULES AND USES THEREOF | AMGEN INC. (US) | 2001-09-20 | — | — | WO | disclosed |
| WO-2001044472-A1 | TNFR/OPG-LIKE MOLECULES AND USES THEREOF | AMGEN, INC. (US) | 2001-06-21 | — | — | WO | disclosed |
| US-4329460-A | ANTICANCER AGENTS, ANTIVIRAL AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1982-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200383979-A1 | TRIARYL COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES | CD274, PDCD1, PDCD1LG2 | NR4A2 456/4885CREBBP 2833/4885GABRA1 2348/4885 |
| US-11266643-B2 | Triaryl compounds for treatment of PD-L1 diseases | CD274, PDCD1, PDCD1LG2 | NR4A2 456/4885CREBBP 2833/4885GABRA1 2348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.